Connect Biopharma (CNTB) Corporate presentation summary

Clinical development highlights

• Rademikibart, a next-generation anti-IL-4Ra antibody, demonstrated a 66% reduction in treatment failure events in acute asthma compared to placebo, with rapid and significant improvements in lung function (FEV₁) and a favorable safety profile in Phase 2 studies.

• Phase 1 IV studies in asthma and COPD showed rapid, sustained FEV₁ improvements with no serious adverse events, supporting both IV and SC administration for acute exacerbations.

• Rademikibart's mechanism leads to reduced eosinophil counts, differentiating it from dupilumab, which increases eosinophils and is associated with higher rates of hypereosinophilia-related adverse events.

• In atopic dermatitis, a Phase 3 study in China showed high response rates (87.1% IGA 0/1, 96.6% EASI-75, 85.3% EASI-90) and a low rate of conjunctivitis, with no significant drug-related safety issues in over 2,000 participants.

• Plans are in place to meet with the FDA in Q4 2026 to discuss Phase 3 development for acute indications in asthma and COPD.

Market opportunity and differentiation

• Acute exacerbation indications in asthma and COPD are seen as a key advantage over existing biologics, with market research indicating significant potential for both acute and chronic use.

• Biologic penetration in asthma remains low, leaving a large untapped market; acute use is expected to drive chronic adoption.

• Rademikibart's rapid onset, less frequent dosing, and differentiated safety profile position it as a best-in-class candidate, with projected peak sales of over $3B for asthma and $2B for COPD.

• New high-yield manufacturing and IV presentation support hospital-friendly pricing and broader market access.

• Exclusive global rights (outside Greater China) and patent protection extend into the 2040s, supporting long-term value creation.

Financial summary

• Cash, cash equivalents, and short-term investments totaled $31.5 million as of June 30, 2026, expected to fund operations for at least one year from August 2026.

• Net loss for the six months ended June 30, 2026, was $37.2 million, with operating expenses of $40.1 million and license/collaboration revenues of $2.9 million.

• Total assets were $43.5 million and shareholders' equity was $26.9 million as of June 30, 2026.